Market research
DBVT DBV Technologies
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 914M
- P/E ratio
- Not available
- Analyst target
- 41.6492
- Dividend yield
- Not available
- Beta
- -0.24
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US23306J3095
- Market cap
- 914M
- P/E ratio
- Not available
- Analyst target
- 41.6492
- Dividend yield
- Not available
- Beta
- -0.24
About
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the DBVT discussion.
5 years, 4 months ago
DBV Technologies S.A is currently in a long term uptrend where the price is trading 24.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
DBV Technologies S.A's total revenue rose by 428.4% to $3M since the same quarter in the previous year.
Its net income has increased by 99.6% to $-160K since the same quarter in the previous year.
Finally, its free cash flow fell by 494.6% to $-129M since the same quarter in the previous year.
Based on the above factors, DBV Technologies S.A gets an overall score of 4/5.